Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
OMER 
Omeros Corporation (OMER)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: OMER (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $22.5
1 Year Target Price $22.5
| 1 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 40.3% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 202.73M USD | Price to earnings Ratio - | 1Y Target Price 22.5 |
Price to earnings Ratio - | 1Y Target Price 22.5 | ||
Volume (30-day avg) 4 | Beta 2.2 | 52 Weeks Range 2.95 - 13.60 | Updated Date 07/10/2025 |
52 Weeks Range 2.95 - 13.60 | Updated Date 07/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.04 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.7% | Return on Equity (TTM) -576.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 349517369 | Price to Sales(TTM) 4.93 |
Enterprise Value 349517369 | Price to Sales(TTM) 4.93 | ||
Enterprise Value to Revenue 8.26 | Enterprise Value to EBITDA -1.49 | Shares Outstanding 58592700 | Shares Floating 56016786 |
Shares Outstanding 58592700 | Shares Floating 56016786 | ||
Percent Insiders 4.4 | Percent Institutions 47.3 |
Upturn AI SWOT
Omeros Corporation
Company Overview
History and Background
Omeros Corporation, founded in 1994, is a biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, and disorders of the central nervous system. It has evolved from early-stage research to a commercial-stage company with FDA-approved products.
Core Business Areas
- Complement-Mediated Diseases: Development of therapies targeting the complement system, a part of the immune system, to treat diseases where complement activation plays a role.
- Central Nervous System Disorders: Development of drugs for CNS disorders, including substance use disorders.
Leadership and Structure
Gregory A. Demopulos, M.D. is the Chairman, President, and Chief Executive Officer. The company has a typical corporate structure with various departments including research, development, clinical, commercial, and administrative functions.
Top Products and Market Share
Key Offerings
- Omeros Corporation: Omeros Corporation's sole product is called OMIDRIA for intraocular irrigating solutions, which is used during cataract surgery to maintain pupil dilation, and can be used to reduce post-operative pain. No reliable market share figures are publicly available.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, focusing on the development of novel therapies for various diseases. It is subject to strict regulatory oversight and requires significant investment in research and development. Government Regulations include FDA, anti-trust, and safety rules. Reimbursement and pricing pressures from health insurers are also high.
Positioning
Omeros is a commercial-stage biopharmaceutical company, they are specialized in complement and G-protein-coupled receptor (GPCR) platforms. Their product focuses on intraocular irrigating solution.
Total Addressable Market (TAM)
The total addressable market for Omeros' therapeutic areas is significant, spanning across complement-mediated diseases and CNS disorders. Omeros's market position for OMIDRIA in cataract surgery is uncertain due to its sole product and lack of disclosed market share.
Upturn SWOT Analysis
Strengths
- Proprietary technology platforms
- FDA-approved product (OMIDRIA)
- Experienced management team
- Targeting large and unmet medical needs
Weaknesses
- Reliance on a single product
- History of financial losses
- Dependence on successful clinical trials for pipeline products
- Competitive landscape
Opportunities
- Expansion of OMIDRIA's market reach
- Advancement of pipeline candidates through clinical trials
- Potential partnerships and collaborations
- Acquisition of complementary technologies or products
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Unfavorable reimbursement policies
- Patent challenges and litigation
Competitors and Market Share
Key Competitors
- JNJ
- ALC
- VTVT
Competitive Landscape
Omeros faces intense competition from established pharmaceutical companies with greater resources. Its success depends on differentiating its products and successfully navigating the regulatory landscape.
Growth Trajectory and Initiatives
Historical Growth: Omeros's historical growth has been uneven, largely dependent on OMIDRIA sales and the success of its clinical development programs.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization of pipeline candidates. Analyst estimates vary widely due to the inherent uncertainty in biopharmaceutical development.
Recent Initiatives: Recent initiatives include advancing its pipeline candidates through clinical trials, seeking regulatory approvals, and exploring potential partnerships.
Summary
Omeros is a biopharmaceutical company with a single FDA-approved product and a pipeline of drug candidates. Its future depends on the successful development and commercialization of its pipeline products. The company's financial performance has been volatile, and it faces significant competition. The company needs to successfully manage it's debt and cash flow while it works to grow its sales and obtain regulatory approvals for its products.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Publicly available information
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Omeros Corporation
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2009-10-08 | Co-Founder, Chairman, CEO & President Dr. Gregory A. Demopulos M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 202 | Website https://www.omeros.com |
Full time employees 202 | Website https://www.omeros.com | ||
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.